Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck

The primary objective of this study is to compare the objective response rate (ORR) of patients with LA-HNSCC, treated with induction of EGFR-ADC MRG003 and anti PD-1 Pucotenlimab versus EGFR-ADC MRG003 alone before chemoradiotherapy. People eligible to participate in this study must be between the ages of 18 and 75 and have locally advanced squamous cell carcinoma of the head and neck requiring treatment with chemoradiotherapy (cisplatin combined with radiotherapy). Half of the research participants will receive MRG003 alone as induction before radiochemotherapy and the other half will receive MRG003 combined with pucotenlimab as induction before radiochemotherapy, then pucotenlimab as adjuvant\* after radiochemotherapy.

NCT Number	NCT06959108
Lead Sponsor	Groupe Oncologie Radiotherapie Tete et Cou Collaborators: Lepu Medical Technology (Beijing) Co., Ltd.
Conditions	Locally Advanced Head and Neck Squamous Cell Carcinoma
Enrollment	106 participants
Start Date	2025-10-13
Primary Completion	2029-06 (estimated)
Study Completion	2029-10 (estimated)
Updated on ClinicalTrials.gov	2026-04-07